Navigation Links
MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
Date:6/28/2008

MOUNTAIN VIEW, Calif., June 28 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today presented data from an in-vitro study evaluating receptor pharmacology of MAP0004, orally inhaled dihydroergotamine (DHE) for the potential treatment of migraine, compared to intravenous (IV) DHE. The study results were among six posters relating to the MAP0004 program that the Company presented at the American Headache Society 50th Annual Scientific Meeting in Boston, MA.

In this receptor pharmacology study, MAP0004 stimulated receptors that relieve migraine at levels comparable to IV DHE, but did not activate receptors associated with side effects frequently seen with IV DHE. In addition, MAP0004 did not affect receptors that have a role in regulating pulmonary function.

"The selective binding of MAP0004 at receptors associated with migraine rather than those associated with side effects offers a mechanistic hypothesis for the favorable safety and efficacy profile of MAP0004 compared to IV DHE that we have observed in our initial clinical studies," said Thomas A. Armer, Ph.D., Chief Scientific Officer of MAP Pharmaceuticals. "The absence of negative effects of MAP0004 on pulmonary function in asthmatic subjects observed in a Phase 2 study is also important because migraine and asthma are frequently co-morbid conditions."

MAP0004 is designed to be self-administered by patients at home via MAP Pharmaceuticals' proprietary Tempo(R) inhaler. In Phase 2 studies with migraneurs and with asthmatics, treatment with MAP0004 was well-tolerated, with no serious adverse events reported. Drug-induced nausea was very low and migraine-associated nausea also decreased with treatment.

The Company presented a poster summariz
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
2. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
3. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
4. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
5. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
6. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
7. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
8. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
9. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
10. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
11. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 15, 2014 As medical device ... Product Labeling) markup language standard, content teams have a ... skills to work with the standard. Starting January 2015, ... three webinars on the benefits and the critical aspects ... will be facilitated by Howard Shatz , DCL,s ...
(Date:12/15/2014)... MINNEAPOLIS , Dec. 15, 2014   ... ), one of the nation,s largest and most ... of its business units, DaVita Clinical Research ... capabilities to further expand its extensive clinical research ... chronic kidney disease (CKD) and end-stage renal disease ...
(Date:12/15/2014)... LONDON and BOSTON , ... the leading GPCR structure-guided drug discovery and development company, ... patents in the United States ... of these patents in the US significantly strengthens the ... the major pharmaceutical markets. The suite of ...
Breaking Medicine Technology:Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2
... proud to announce its conference keynote speakers include: Centers ... CBS Evening News Anchor Katie Couric; U.S. ... U.S. Secretary of Commerce Gary Locke. Each will address ... leaders in Washington, D.C. October 18-20 during AdvaMed ...
... Arlington Medical Resources (AMR), a provider of premier ... finds that more than half of all European inpatients ... Sanofi-Aventis,s Clexane (marketed as Lovenox in the U.S. and ... The European Hospital Anticoagulant Market Guide is a ...
Cached Medicine Technology:AdvaMed 2010 Keynote Speakers Announced 2AdvaMed 2010 Keynote Speakers Announced 3European Hospital Anticoagulant Market Dominated by Sanofi-Aventis's Clexane 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... 26 As the voice of the global ... Organizations (ACRO) had the honor of presenting before ... 26th, 2009 in Tokyo. ACRO Chair Derek Winstanly, ... and ACRO Executive Director Douglas Peddicord, Ph.D. addressed ...
... (PHILADELPHIA) Researchers from Thomas Jefferson University have identified ... in the growth and migration of prostate cancer cells, ... in the American Journal of Pathology . , ... of the protein when compared to normal prostate cells, ...
... Feb. 26 On Monday, March 2, the ... to become "The Healthiest Company in Green Bay." The firm ... them at that goal.The 30-person agency is collaborating with Health ... ( www.hatwork.com ). The title of "Healthiest Company in Green ...
... Physicians Offers Secure Message Capability to Facilitate ... Human Science, Inc. (HSI), a Rockville ... launch of an innovative software service that ... care in a secure environment. PatientCarenet.Org ...
... monitoring, and biostatistics for several early-stage clinical trials and registries ... ... Clinipace , a growing clinical research solutions company, today announced that ... aggregate, more than $2.8 million., , ,With a focus on emerging ...
... Feb. 26 Orthopaedic surgeon Michael L. Parks, MD, ... American Academy of Orthopaedic Surgeons (AAOS) ( ... Vegas. He will serve the Academy as Member-at-Large ... specializes in the reconstruction of arthritic conditions affecting the ...
Cached Medicine News:Health News:ACRO Presents at Japan CRO Association Commemorative Symposium 2Health News:Proepithelin encourages cell growth and migration in prostate cancer 2Health News:Arketype to Become Green Bay's Healthiest Company in One Year -- Wanna Bet? 2Health News:Arketype to Become Green Bay's Healthiest Company in One Year -- Wanna Bet? 3Health News:Human Science, Inc. Launches PatientCarenet.Org 2Health News:Human Science, Inc. Launches PatientCarenet.Org 3Health News:Clinipace Recently Awarded $2.8 Million to Manage Three New Clinical Projects 2Health News:Michael L. Parks, MD, Elected to the American Academy of Orthopaedic Surgeons Board of Directors 2
... the art in inverted microscopy from Zeiss. ... range of ICS objectives, with innovative condensers ... an unusual scope of sophisticated documentation and ... designed. And Axiovert 200 M, fully motorized, ...
... TS100 is an innovative and efficient ... tool complements any research facility. Improved ... Nikon offers the TS100 binocular and ... model comes with a photo port ...
... direct digital output. Three-chip color camera for ... array of high-quality color video cameras give ... you need for an efficient viewing experience. ... image of your specimen that can be ...
... Tech GT-Capture digital camera photomicrographic system can ... such as Olympus, Leica, Nikon, and Zeiss, ... transferring images over the Internet easy and ... a performance-proven Nikkor lens. The system records ...
Medicine Products: